Your Article Summary
See Latest ArticlesScales as outcome measures for Alzheimers disease
Alzheimer's & Dementia , 06/30/09
Black R et al. - The assessment of patient outcomes in clinical trials of new therapeutics for Alzheimer's disease (AD) continues to evolve. In addition to assessing drugs for symptomatic relief, an increasing number of trials are focusing on potential disease-modifying agents. Moreover, participants with AD are being studied earlier in their course of disease. As a result, the limitations of current outcome measures have become more apparent, as has the need for better instruments.
Related Articles
Does Diabetes Speed Up Memory Loss In Alzheimers Disease?
ScienceDaily, 10/28/09
Relevance Score: 71%
High Blood Pressure Likely in Alzheimers Offspring
MedLinePlus, 11/04/09
Relevance Score: 70%
Activated astrocytes: a therapeutic target in Alzheimer's disease?
Expert Review of Neurotherapeutics, 11/19/09
Relevance Score: 69%
Protective Role For Copper In Alzheimers Disease
ScienceDaily, 10/14/09
Relevance Score: 69%
All-trans retinoic acid as a novel therapeutic strategy for Alzheimer's disease
Expert Review of Neurotherapeutics, 11/19/09
Relevance Score: 68%
Today in Dementia...keeping you current
Receive free subspecialty "5-minute updates" via email
Inflammation: A bridge between postoperative cognitive dysfunction and Alzheimer's disease
Medical Hypotheses, 12/08/09
Repetitive Thinking as a Psychological Cognitive Style in Midlife Is Associated with Lower Risk for Dementia Three Decades Later
Dementia and Geriatric Cognitive Disorders, 12/08/09
Increased Serum IL-1-beta Level in Alzheimer's Disease and Mild Cognitive Impairment
Dementia and Geriatric Cognitive Disorders, 12/08/09